Document is current
Any future updates will be listed below
-
Authors
Gigan, Julien P https://orcid.org/0000-0002-3799-6310
Garcia-Gonzalez, Paulina
Pilotti, Angelo https://orcid.org/0009-0005-4288-1410
Galliot, Lou
Reynaud, Alexandre
Ghaffar, Yoan https://orcid.org/0009-0008-2937-4336
Flores-Santibáñez, Felipe
Ghafoori, Sara https://orcid.org/0009-0003-2335-6368
Seillier, Eve
Lavignolle-Heguy, Rosario https://orcid.org/0000-0002-6642-3597
Barros, Daniela
Bret, Caroline
Fichaux, Sharon
Combes, Alexis
Bani, Alessandro
Rua, Rejane
Gatti, Evelina https://orcid.org/0000-0002-0667-0799
Nal-Rogier, Béatrice https://orcid.org/0000-0003-3452-7524
Rocchi, Stéphane
Moreaux, Jérôme https://orcid.org/0000-0002-5717-3207
Pierre, Philippe https://orcid.org/0000-0003-0863-8255
Argüello, Rafael J https://orcid.org/0000-0001-9785-3883
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-20-CE14-0028)
Agence Nationale de la Recherche (ANR-22-CE15-0015-02)
Transcan (https://transcan.eu/output-results/funded-projects/talete.kl)
Institut National Du Cancer (SIRIC Pediacriex "SOUTH-Rock")
Institut National Du Cancer (HRHG Imagine project)
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (Immerge - 10111992)
EC | Horizon Europe | Global Challenges & European Industrial Competitiveness | HORIZON EUROPE Health (Beatsep)
- License Information
-
More Information
Article History
Received: 22 April 2025
Revised: 28 May 2026
Accepted: 1 June 2026
First Online: 29 June 2026
Disclosure and competing interests statement
: Stéphane Rocchi is the co-founder of BIPER Therapeutics. Rafael Argüello is co-founder of GammaOmics. The remaining authors declare no competing interests.
